Loading...
01/10 16:24
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
Total operating expenses Declined 9% compared to the second quarter of 2024, primarily reflecting lower personnel costs and lower research and development expenses.
Net cash used in operating activities (Q2 2025) $6.3 million, compared to $6.7 million in Q2 2024, showing a reduction due to strong cost management.
Net cash used in operating activities (First half of 2025) $10.6 million, down 30% over the same period in the prior year, attributed to cost management.
Revenue (Q2 2025) Over $400,000, contributing to a first half total of over $650,000, with total revenue up 15% in the first half. The increase is attributed to the first revenue from sales of a human product, Nu.Q NETs.
Cash and cash equivalents (End of Q2 2025) Approximately $2.3 million, compared to $3.3 million at the end of 2024. Receipts included $6 million in net proceeds from a convertible loan note and $1.2 million from a registered direct offering post-quarter.
Net loss (First half of 2025) Improved by 24%, reflecting better financial management and reduced expenses.
Nu.Q NETs: First revenue recorded from sales of CE-marked Nu.Q NETs automated product in Europe. Sales have continued in Q2 2025, with 11 hospital networks in 5 countries placing orders. Discussions with over 10 other hospital networks are ongoing.
Nu.Q Cancer: Progress in lung cancer screening study in Taiwan, with interim findings to be presented at ESMO in October. Potential inclusion in national lung cancer screening programs could represent a market exceeding $1 billion annually.
Nu.Q Discover: Serving over 20 clients worldwide, with growing demand for Nu.Q assays as exploratory biomarkers in clinical trials. Largest project projected revenue in hundreds of thousands of dollars.
Licensing Agreements: Confidential discussions with over 10 companies, including 7 with a combined market value exceeding $600 billion. Goal to secure multiple licensing agreements in human diagnostics, mirroring veterinary success.
Global Expansion: Potential inclusion of Nu.Q Cancer in national lung cancer screening programs in Taiwan, U.S., U.K., and France. Expansion of Nu.Q NETs sales to more hospital networks globally.
Cost Management: Total operating expenses declined 9% in Q2 2025 compared to Q2 2024. Net cash used in operating activities reduced by 30% in the first half of 2025.
Revenue Growth: Revenue increased by 15% in the first half of 2025, with total revenue reaching over $650,000. First revenue recorded for sales of human product Nu.Q NETs.
Commercialization Focus: 2025 is focused on commercializing the Nu.Q platform in human diagnostics. Progress in licensing discussions and clinical validations to support commercialization.
Technology Platform: Nu.Q platform demonstrated versatility across cancer, sepsis, and veterinary applications. Positioned for broad applicability and potential partnerships.
Revenue unpredictability: Revenues remain fairly lumpy and difficult to predict from one quarter to the next, making financial forecasting challenging.
Cash reserves: Cash and cash equivalents at the end of the quarter totaled approximately $2.3 million, which is a decline from $3.3 million at the end of 2024, indicating potential liquidity concerns.
Dependence on licensing agreements: Achieving cash neutrality for 2025 is dependent on executing one or more licensing agreements in the human space with significant upfront payments, which introduces uncertainty.
Regulatory hurdles: The company is navigating regulatory filings under the IVDR framework, which could delay product approvals and commercialization.
Market adoption challenges: The adoption of Nu.Q tests into national lung cancer screening programs and routine clinical practice is not guaranteed and depends on positive study results and government approvals.
Competitive pressures: The company is operating in highly competitive markets, including cancer diagnostics and sepsis, with other players potentially offering alternative solutions.
Economic uncertainties: The company’s financial health and ability to secure licensing deals may be impacted by broader economic conditions.
Product validation and scalability: The success of the Nu.Q platform depends on the validation of ongoing studies and the scalability of its technology for widespread adoption.
Dependence on partnerships: The company’s strategy heavily relies on partnerships with large companies and hospital networks, which may not materialize as expected.
Supply chain and operational risks: The company is focused on central lab automation and scaling up production, which could face operational or supply chain challenges.
Revenue Guidance: The company will not be providing revenue guidance for 2025 at this point in time due to the early stage of commercialization and the unpredictable nature of revenues.
Cash Neutrality Goal: One of the key financial goals for 2025 is to be cash neutral on a full-year basis. This depends on executing one or more licensing agreements in the human space with significant upfront payments, receiving milestone payments in the veterinary space, and reducing expenditures.
Licensing Agreements: The company is in confidential discussions with over 10 companies, aiming to secure multiple licensing agreements in the human diagnostic space. These agreements are expected to include ongoing revenue and large milestone payments.
Nu.Q Cancer Test: The final lung cancer screening study in Taiwan is progressing rapidly, with interim analysis to be presented in October 2025. Positive findings could position the Nu.Q test for inclusion in national lung cancer screening programs, representing a potential market exceeding $1 billion annually across Taiwan, U.S., U.K., and France.
Nu.Q NETs Test: The company is progressing with the commercialization of the Nu.Q NETs test, with 11 hospital networks in 5 countries currently assessing its clinical utility. Licensing discussions are ongoing, with the total addressable market for the Nu.Q NETs assay estimated to exceed $10 billion annually.
Nu.Q Discover: The Nu.Q Discover platform is serving over 20 clients worldwide and is expected to see strong revenue growth in 2025. The company is exploring co-marketing partnerships to meet global demand.
Strategic Focus for 2025: The company is focused on signing licensing deals in the human diagnostic space, progressing discussions with national lung screening programs, and commercializing its technology to make it accessible worldwide.
The selected topic was not discussed during the call.
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
The earnings call presents mixed signals. While there are positive aspects like revenue growth, cost management, and milestone payments, the absence of revenue guidance and declining cash position raise concerns. The Q&A section reveals uncertainty in revenue predictability and challenges in maintaining cost levels. Overall, the lack of specific guidance and potential financial risks balance out the positives, suggesting a neutral sentiment towards the stock price movement.
The earnings call presents mixed signals: strong revenue growth and reduced expenses are positive, but lack of 2025 guidance and regulatory uncertainties are concerns. The Q&A reveals cautious optimism about new projects and milestone payments, but management's unclear responses on some topics raise doubts. Overall, the absence of clear guidance and competitive pressures balance out the positive financial metrics, leading to a neutral sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
